Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

3.20USD
16 Feb 2018
Change (% chg)

$0.13 (+4.23%)
Prev Close
$3.07
Open
$3.10
Day's High
$3.24
Day's Low
$3.07
Volume
1,537,973
Avg. Vol
478,723
52-wk High
$5.66
52-wk Low
$2.60

Select another date:

Wed, Dec 20 2017

BRIEF-Achillion Initiates Phase I First-In Study Of ACH-5228

* ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D

BRIEF-Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY

BRIEF-Achillion announces pricing of secondary offering of common stock

* Achillion announces pricing of secondary offering of common stock

BRIEF-Achillion announces proposed secondary offering of common stock

* Achillion announces proposed secondary offering of common stock

BRIEF-Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

* Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

BRIEF-Achillion says ACH-4471 granted orphan drug designation by FDA

* Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria

BRIEF-Achillion Q3 loss per share $0.14

* Achillion reports third quarter 2017 financial results and provides update on clinical programs

BRIEF-RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing‍​

* RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing‍​ Source text: (http://bit.ly/2wXrbF8) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Achillion announces termination of worldwide collaboration for hepatitis c with Janssen

* Achillion announces termination of worldwide collaboration for hepatitis c with Janssen Further company coverage:

Select another date: